Full Press Release Details
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #IMS26--BMS Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial
BMY Positive Sentiment
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
Key Takeaway: Bristol Myers Squibb has announced the first presentation of results for ZENBEXUS™ (iberdomide) in combination with Daratumumab from the Phase 3 EXCALIBER-RRMM trial. This trial focuses on patients with relapsed or refractory multiple myeloma, showcasing the potential of this combination therapy. The announcement marks a significant step in the ongoing development of innovative treatments for this patient population.
Market Sentiment Analysis
POSITIVE FACTORS
- First presentation of results for ZENBEXUS™ is a significant milestone.
- Combination therapy shows promise for relapsed or refractory multiple myeloma.
- Bristol Myers Squibb continues to advance its oncology pipeline.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+26%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Pneumococcal polysaccharide vaccine
Phase 3 · Multiple Sclerosis
Frequently Asked Questions
What is ZENBEXUS™?
ZENBEXUS™ is iberdomide, a drug developed for treating multiple myeloma.
What trial was announced by Bristol Myers Squibb?
The Phase 3 EXCALIBER-RRMM trial results were announced.
What is the focus of the EXCALIBER-RRMM trial?
The trial focuses on patients with relapsed or refractory multiple myeloma.
What combination therapy was presented?
The combination of ZENBEXUS™ and Daratumumab was presented.